To protect and defend: Central nervous system prophylaxis in patients with non-Hodgkin's lymphoma

Hwee Yong Lim, Eckhard Thiel, Michael J. Glantz

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Purpose of review Despite remarkable advances in the treatment of non-Hodgkin's lymphoma of all histologie subtypes, nervous system involvement remains a dire complication associated with a rapid decline in quality of life, few good treatment options, and a short overall survival. In fact, these advances in treatment may be fueling an increase in the frequency of nervous system relapse. A better understanding of the epidemiology, diagnostic techniques, and options for prophylaxis of the central nervous system may be one of the best strategies for improving the outcome in patients with non-Hodgkin's lymphoma. Recent findings Central nervous system relapse in patients with non-Hodgkin's lymphoma is, typically, an early event, occurs in the setting of well described histologic, demographic, and clinical risk factors, and is characterized primarily by the involvement of the cerebrospinal fluid. Cerebrospinal fluid prophylaxis in high-risk patients appears to be effective in reducing the frequency of this complication. Summary More aggressive attention to diagnosis, focused on cytologie and flow cytometric evaluation of the cerebrospinal fluid in high-risk patients, will identify more patients with early and potentially more treatable central nervous system lymphoma. Cerebrospinal fluid prophylaxis appears to reduce the frequency of this complication in high-risk populations, but controversy remains regarding the most important high-risk characteristics and the optimum prophylactic interventions.

Original languageEnglish (US)
Pages (from-to)495-501
Number of pages7
JournalCurrent opinion in oncology
Volume20
Issue number5
DOIs
StatePublished - Sep 1 2008

Fingerprint

Non-Hodgkin's Lymphoma
Central Nervous System
Cerebrospinal Fluid
Nervous System
Recurrence
Lymphoma
Epidemiology
Therapeutics
Quality of Life
Demography
Survival
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{0fe914cc0f3245ada26b62d3c467e217,
title = "To protect and defend: Central nervous system prophylaxis in patients with non-Hodgkin's lymphoma",
abstract = "Purpose of review Despite remarkable advances in the treatment of non-Hodgkin's lymphoma of all histologie subtypes, nervous system involvement remains a dire complication associated with a rapid decline in quality of life, few good treatment options, and a short overall survival. In fact, these advances in treatment may be fueling an increase in the frequency of nervous system relapse. A better understanding of the epidemiology, diagnostic techniques, and options for prophylaxis of the central nervous system may be one of the best strategies for improving the outcome in patients with non-Hodgkin's lymphoma. Recent findings Central nervous system relapse in patients with non-Hodgkin's lymphoma is, typically, an early event, occurs in the setting of well described histologic, demographic, and clinical risk factors, and is characterized primarily by the involvement of the cerebrospinal fluid. Cerebrospinal fluid prophylaxis in high-risk patients appears to be effective in reducing the frequency of this complication. Summary More aggressive attention to diagnosis, focused on cytologie and flow cytometric evaluation of the cerebrospinal fluid in high-risk patients, will identify more patients with early and potentially more treatable central nervous system lymphoma. Cerebrospinal fluid prophylaxis appears to reduce the frequency of this complication in high-risk populations, but controversy remains regarding the most important high-risk characteristics and the optimum prophylactic interventions.",
author = "Lim, {Hwee Yong} and Eckhard Thiel and Glantz, {Michael J.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1097/CCO.0b013e32830b829e",
language = "English (US)",
volume = "20",
pages = "495--501",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

To protect and defend : Central nervous system prophylaxis in patients with non-Hodgkin's lymphoma. / Lim, Hwee Yong; Thiel, Eckhard; Glantz, Michael J.

In: Current opinion in oncology, Vol. 20, No. 5, 01.09.2008, p. 495-501.

Research output: Contribution to journalReview article

TY - JOUR

T1 - To protect and defend

T2 - Central nervous system prophylaxis in patients with non-Hodgkin's lymphoma

AU - Lim, Hwee Yong

AU - Thiel, Eckhard

AU - Glantz, Michael J.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose of review Despite remarkable advances in the treatment of non-Hodgkin's lymphoma of all histologie subtypes, nervous system involvement remains a dire complication associated with a rapid decline in quality of life, few good treatment options, and a short overall survival. In fact, these advances in treatment may be fueling an increase in the frequency of nervous system relapse. A better understanding of the epidemiology, diagnostic techniques, and options for prophylaxis of the central nervous system may be one of the best strategies for improving the outcome in patients with non-Hodgkin's lymphoma. Recent findings Central nervous system relapse in patients with non-Hodgkin's lymphoma is, typically, an early event, occurs in the setting of well described histologic, demographic, and clinical risk factors, and is characterized primarily by the involvement of the cerebrospinal fluid. Cerebrospinal fluid prophylaxis in high-risk patients appears to be effective in reducing the frequency of this complication. Summary More aggressive attention to diagnosis, focused on cytologie and flow cytometric evaluation of the cerebrospinal fluid in high-risk patients, will identify more patients with early and potentially more treatable central nervous system lymphoma. Cerebrospinal fluid prophylaxis appears to reduce the frequency of this complication in high-risk populations, but controversy remains regarding the most important high-risk characteristics and the optimum prophylactic interventions.

AB - Purpose of review Despite remarkable advances in the treatment of non-Hodgkin's lymphoma of all histologie subtypes, nervous system involvement remains a dire complication associated with a rapid decline in quality of life, few good treatment options, and a short overall survival. In fact, these advances in treatment may be fueling an increase in the frequency of nervous system relapse. A better understanding of the epidemiology, diagnostic techniques, and options for prophylaxis of the central nervous system may be one of the best strategies for improving the outcome in patients with non-Hodgkin's lymphoma. Recent findings Central nervous system relapse in patients with non-Hodgkin's lymphoma is, typically, an early event, occurs in the setting of well described histologic, demographic, and clinical risk factors, and is characterized primarily by the involvement of the cerebrospinal fluid. Cerebrospinal fluid prophylaxis in high-risk patients appears to be effective in reducing the frequency of this complication. Summary More aggressive attention to diagnosis, focused on cytologie and flow cytometric evaluation of the cerebrospinal fluid in high-risk patients, will identify more patients with early and potentially more treatable central nervous system lymphoma. Cerebrospinal fluid prophylaxis appears to reduce the frequency of this complication in high-risk populations, but controversy remains regarding the most important high-risk characteristics and the optimum prophylactic interventions.

UR - http://www.scopus.com/inward/record.url?scp=59649123407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649123407&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32830b829e

DO - 10.1097/CCO.0b013e32830b829e

M3 - Review article

C2 - 19106650

AN - SCOPUS:59649123407

VL - 20

SP - 495

EP - 501

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -